

TITAN PHARMACEUTICALS INC  
Form 8-K  
October 16, 2012

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act 1934

Date of Report (Date of earliest event reported): October 13, 2012

## Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**0-27436**  
(Commission  
File Number)

**94-3171940**  
(IRS Employer  
Identification No.)

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

400 Oyster Point Blvd., Suite 505,

South San Francisco, CA  
(Address of Principal Executive Offices)

94080  
(Zip Code)

Registrant's telephone number, including area code: 650-244-4990

(Former Name or Former Address, is Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On October 13, 2012, the six-month series B warrants (the Series B Warrants ) issued by Titan Pharmaceuticals, Inc. (the Company ) in connection with its April 2012 registered direct offering expired. Series B Warrants to purchase an aggregate of 5,761,765 shares of the Company s common stock at an exercise price of \$0.85 per share were exercised prior to the expiration date, resulting in gross proceeds to the Company of \$4,897,500. Series B Warrants to purchase an aggregate of 755,883 shares of common stock expired unexercised.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TITAN PHARMACEUTICALS, INC.

By: /s/ Sunil Bhonsle  
Name: Sunil Bhonsle  
Title: President

Dated: October 16, 2012